Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIPARP | Q7Z3E1 | 6/20 | 0.48 |
| ▸ | TNF | P01375 | 6/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25898373 | 0.88 | NPC1 (0.40) | TIPARPTNFGRM2HDAC3HDAC1 | |
| SCHEMBL25898617 | 0.88 | TIPARP (0.41) | TIPARPTNFGRM2 | |
| SCHEMBL26786720 | 0.86 | TIPARP (0.44) | TIPARPTNFGRM2HDAC3HDAC1 | |
| SCHEMBL25898769 | 0.84 | GRM2 (0.40) | TIPARPGRM2 | |
| SCHEMBL25897799 | 0.84 | TIPARP (0.41) | TIPARPTNFGRM2HDAC3HDAC1 | |
| SCHEMBL25899760 | 0.82 | TIPARP (0.41) | TIPARPTNFGRM2HDAC3HDAC1 | |
| SCHEMBL25898347 | 0.82 | BRD4 (0.40) | TIPARPTNFGRM2HDAC3HDAC1 | |
| SCHEMBL25898605 | 0.80 | TIPARP (0.49) | TIPARPTNFGRM2HDAC3HDAC1 | |
| SCHEMBL25898123 | 0.80 | GRM2 (0.43) | TIPARPTNFGRM2HDAC3HDAC1 | |
| SCHEMBL25898391 | 0.79 | TIPARP (0.46) | TIPARPTNFGRM2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | TIPARP 491/4885TNF 4831/4885GRM2 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.